During the past decade, Klinikum Gütersloh conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Klinikum Gütersloh" #1 sponsor was "Daiichi Sankyo, Inc." with 2 trials, followed by "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 2 trials sponsored, "AGO Research GmbH" with 1 trials sponsored, "AGO Study Group" with 1 trials sponsored and "Abbott Medical Devices" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Klinikum Gütersloh" #1 collaborator was "Daiichi Sankyo Deutschland GmbH" with 1 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator, "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 1 trials as a collaborator, "Heart Center Leipzig - University Hospital" with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Klinikum Gütersloh" are "Lymphoma" (2 trials), "Atrial Fibrillation" (1 trials), "CD20+ Aggressive B-Cell Lymphoma" (1 trials), "Chronic Heart Failure" (1 trials) and "Fallopian Tube Cancer" (1 trials). Many other conditions were trialed in "Klinikum Gütersloh" in a lesser frequency.

Most popular intervention types in "Klinikum Gütersloh" are "Drug" (7 trials), "Biological" (2 trials), "Radiation" (2 trials), "Device" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bevacizumab" (2 trials), "Edoxaban" (2 trials), "cyclophosphamide" (2 trials), "doxorubicin hydrochloride" (2 trials) and "filgrastim" (2 trials). Other intervention names were less common.

The vast majority of trials in "Klinikum Gütersloh" are 7 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Klinikum Gütersloh". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Klinikum Gütersloh, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Klinikum Gütersloh, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".